Wanda Terrell
Internal Medicine · Saint Louis, MONPI 1558391938
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 401 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,127 and has fallen 89.7% since, to $220 in 2023. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$844
- Novo Nordisk$701
- Pfizer$645
- GSK$606
- AbbVie$496
- Lilly USA, LLC$372
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,85298%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $844 |
| Novo Nordisk | 51 | $701 |
| Pfizer | 42 | $645 |
| GSK | 51 | $606 |
| AbbVie(2 entities) | 36 | $496 |
| Lilly USA, LLC | 25 | $372 |
| Boehringer Ingelheim | 18 | $297 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $286 |
| Biohaven Pharmaceuticals, Inc. | 11 | $216 |
| Sanofi-aventis U.S. LLC | 12 | $203 |
| Astellas Pharma US Inc | 8 | $189 |
| Arbor Pharmaceuticals, Inc. | 14 | $185 |
| Merck | 10 | $148 |
| Johnson & Johnson | 7 | $102 |
| Sunovion Pharmaceuticals Inc. | 7 | $97 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $87 |
| Amgen | 4 | $66 |
| Amarin Pharma, Inc. | 4 | $53 |
| Bristol Myers Squibb | 1 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $32 |
| Dexcom, Inc. | 2 | $27 |
| Daiichi Sankyo Inc. | 2 | $25 |
| Zyla Life Sciences, Inc. | 2 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Abbott | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Optos, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Gilead | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$5,966 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 17 | $262 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.